Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | UQCRB | P14927 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482520 | 0.88 | KIF11 (0.46) | CA2IDH1CYSLTR2CYSLTR1PPARG | |
| SCHEMBL6475717 | 0.86 | CA2 (0.43) | CA2PTGS1PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL6481745 | 0.85 | EPHX2 (0.41) | IKBKBEPHX2PTPN11CA2UQCRB | |
| SCHEMBL6479679 | 0.84 | KDM1A (0.42) | CA2PTGS1PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL6474786 | 0.84 | LTB4R (0.41) | CA2PTGS1PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL6479428 | 0.84 | PPARA (0.41) | IKBKBEPHX2CYSLTR2CYSLTR1PPARG | |
| SCHEMBL6475739 | 0.83 | PTPN1 (0.48) | CA2PTGS1PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL6483863 | 0.83 | PPARA (0.47) | CA2PTGS1PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL6475312 | 0.83 | CA2 (0.40) | CA2PTGS1PTGS2CYSLTR2CYSLTR1 | |
| SCHEMBL6474114 | 0.82 | IKBKB (0.40) | IKBKBEPHX2UQCRBCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930131-B2 | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | GPR119, INSR, SLC5A1 | IKBKB 198/4885EPHX2 4462/4885PTPN11 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.